Sotagliflozin

SKU: orb1304078

Description

Sotagliflozin (LP-802034) is a dual SGLT1 and SGLT2 inhibitor with oral bioavailability, investigated for its antihyperglycemic potential. It is used in research on diabetes and heart failure, with studies demonstrating its effects on glucose homeostasis in both in vitro assays and in vivo models.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1018899-04-1
• MW: 424.94
• Purity: 99.78%
• Formula: C₂₁H₂₅ClO₅S
• SMILES: CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1
• Target: SGLT
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:262.5 mg/mL (617.73 mM);Ethanol:14 mg/mL (32.95 mM)

Bioactivity

• Target IC50:
  SGLT1:62 nM (mouse)|SGLT1:36 nM (human)|SGLT2:0.6 nM (mouse)|SGLT2:1.8 nM (human)
• In Vivo:
  In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements.
• In Vitro:
  LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively.

Storage & Handling

• Storage: keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, LP802034, LP-802034, LP 802034, inhibit, LX4211, LX-4211, LX 4211, SGLT1, SGLT2, SGLT, Sotagliflozin, Sodium-dependent glucose cotransporters

Compound Identifiers

PubChem CID

24831714